109 related articles for article (PubMed ID: 16957420)
21. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells.
Hennequin C; Giocanti N; Favaudon V
Cancer Res; 1996 Apr; 56(8):1842-50. PubMed ID: 8620502
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death.
Mitchell C; Hamed HA; Cruickshanks N; Tang Y; Bareford MD; Hubbard N; Tye G; Yacoub A; Dai Y; Grant S; Dent P
Cancer Biol Ther; 2011 Aug; 12(3):215-28. PubMed ID: 21642769
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
Kahán Z; Sun B; Schally AV; Arencibia JM; Cai RZ; Groot K; Halmos G
Cancer; 2000 Mar; 88(6):1384-92. PubMed ID: 10717621
[TBL] [Abstract][Full Text] [Related]
24. All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells.
Wang Q; Wieder R
Oncogene; 2004 Jan; 23(2):426-33. PubMed ID: 14724571
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity of taxotere (RP 56976, NSC 628503), a new taxol analog, in experimental ovarian cancer.
Boven E; Venema-Gaberscek E; Erkelens CA; Bissery MC; Pinedo HM
Ann Oncol; 1993 Apr; 4(4):321-4. PubMed ID: 8100146
[TBL] [Abstract][Full Text] [Related]
26. Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells.
Hanauske AR; Degen D; Hilsenbeck SG; Bissery MC; Von Hoff DD
Anticancer Drugs; 1992 Apr; 3(2):121-4. PubMed ID: 1356030
[TBL] [Abstract][Full Text] [Related]
27. Candidate markers that associate with chemotherapy resistance in breast cancer through the study on Taxotere-induced damage to tumor microenvironment and gene expression profiling of carcinoma-associated fibroblasts (CAFs).
Rong G; Kang H; Wang Y; Hai T; Sun H
PLoS One; 2013; 8(8):e70960. PubMed ID: 23951052
[TBL] [Abstract][Full Text] [Related]
28. BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanine.
Gu Y; Helenius M; Väänänen K; Bulanova D; Saarela J; Sokolenko A; Martens J; Imyanitov E; Kuznetsov S
Sci Rep; 2016 Jun; 6():28217. PubMed ID: 27313062
[TBL] [Abstract][Full Text] [Related]
29. Metastasis of hormone-independent breast cancer to lung and bone is decreased by alpha-difluoromethylornithine treatment.
Richert MM; Phadke PA; Matters G; DiGirolamo DJ; Washington S; Demers LM; Bond JS; Manni A; Welch DR
Breast Cancer Res; 2005; 7(5):R819-27. PubMed ID: 16168128
[TBL] [Abstract][Full Text] [Related]
30. HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1.
Hu M; Wang J; Chen P; Reilly RM
Bioconjug Chem; 2006; 17(5):1280-7. PubMed ID: 16984139
[TBL] [Abstract][Full Text] [Related]
31. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
32. Effects of the combination of RAD001 and docetaxel on breast cancer stem cells.
Zhang X; Zhang S; Liu Y; Liu J; Ma Y; Zhu Y; Zhang J
Eur J Cancer; 2012 Jul; 48(10):1581-92. PubMed ID: 22420943
[TBL] [Abstract][Full Text] [Related]
33. Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A.
Ciardiello F; Caputo R; Pomatico G; De Laurentiis M; De Placido S; Bianco AR; Tortora G
Int J Cancer; 2000 Mar; 85(5):710-5. PubMed ID: 10699953
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
35. Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor models.
Daouti S; Higgins B; Kolinsky K; Packman K; Wang H; Rizzo C; Moliterni J; Huby N; Fotouhi N; Liu M; Goelzer P; Sandhu HK; Li JK; Railkar A; Heimbrook D; Niu H
Mol Cancer Ther; 2010 Jan; 9(1):134-44. PubMed ID: 20053779
[TBL] [Abstract][Full Text] [Related]
36. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status.
Desai NP; Trieu V; Hwang LY; Wu R; Soon-Shiong P; Gradishar WJ
Anticancer Drugs; 2008 Oct; 19(9):899-909. PubMed ID: 18766004
[TBL] [Abstract][Full Text] [Related]
37. U0126, a mitogen-activated protein kinase kinase 1 and 2 (MEK1 and 2) inhibitor, selectively up-regulates main isoforms of CYP3A subfamily via a pregnane X receptor (PXR) in HepG2 cells.
Smutny T; Bitman M; Urban M; Dubecka M; Vrzal R; Dvorak Z; Pavek P
Arch Toxicol; 2014 Dec; 88(12):2243-59. PubMed ID: 24819614
[TBL] [Abstract][Full Text] [Related]
38. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.
Bissery MC; Guénard D; Guéritte-Voegelein F; Lavelle F
Cancer Res; 1991 Sep; 51(18):4845-52. PubMed ID: 1680023
[TBL] [Abstract][Full Text] [Related]
39. MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells.
Yacoub A; Mitchell C; Hong Y; Gopalkrishnan RV; Su ZZ; Gupta P; Sauane M; Lebedeva IV; Curiel DT; Mahasreshti PJ; Rosenfeld MR; Broaddus WC; James CD; Grant S; Fisher PB; Dent P
Cancer Biol Ther; 2004 Aug; 3(8):739-51. PubMed ID: 15197348
[TBL] [Abstract][Full Text] [Related]
40. Taxotere-5'-deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cells.
Fischel JL; Ferrero JM; Formento P; Ciccolini J; Renée N; Formento JL; Milano G
Anticancer Drugs; 2005 Mar; 16(3):309-16. PubMed ID: 15711183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
